The recombinant virus used in the AuRx therapy has been genetically
engineered to remove a gene that is responsible for the ability
of the virus to activate signaling pathways which cause cell proliferation
and ultimately may result in neoplastic transformation. The deleted
gene is also required for HSV-2 replication and reactivation from
ganglionic latency. Therefore, the recombinant virus used in the
AuRx therapy has been attenuated to prevent the outbreak of the
disease in previously infected individuals.
Since there is a 50% similarity (genetic homology) between HSV-l
and HSV-2, it is likely that the vaccine will also prevent HSV-1
recurrences, however, demonstrating this will require a large clinical
trial over an extended period of time.